No Prescription |
 |
 | ||
|
REVOCON Nitoman |
|
| ||
No Prescription » Prescription Drugs 14 » REVOCON Nitoman Tetrabenazine is a drug for the symptomatical treatment of hyperkinetic movement disorder and is marketed under the trade names Nitoman in Canada and Xenazine in New Zealand and some parts of Europe and is also available in the USA as an orphan drug. Tetrabenazine is used as a treatment but not a cure for hyperkinetic disorders[2] such as:Huntington's Disease - specificially the chorea associated with it Tourette's Syndrome and other tic disorders Tardive dyskinesia a serious and sometimes irreversible side effect of long-term use of many antipsychotics mainly typical antipsychotics Hemiballismus spontaneous flinging limb movements due to subthalamic nucleus damage Buy REVOCON Nitoman and other Prescription Drugs 14 products online at Medstore. Buy Online at Medstore - Click Here!
About REVOCON Nitoman: Product Type: Prescription Drugs 14 REVOCON ( Nitoman/Xenamine GENERIC Tetrabenazine ) REVOCON (Nitoman/Xenamine GENERIC Tetrabenazine) Nitoman/Xenamine GENERIC Tetrabenazine 25 mg Nitoman/Xenamine GENERIC Tetrabenazine REVOCON
View more Prescription Drugs 14 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
